Free Trial

Sarepta Therapeutics (SRPT) Stock Price, News & Analysis

Sarepta Therapeutics logo
$17.10 +1.19 (+7.48%)
Closing price 08/4/2025 04:00 PM Eastern
Extended Trading
$16.92 -0.18 (-1.02%)
As of 05:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Sarepta Therapeutics Stock (NASDAQ:SRPT)

Key Stats

Today's Range
$15.34
$17.28
50-Day Range
$11.93
$43.01
52-Week Range
$10.41
$145.00
Volume
17.52 million shs
Average Volume
20.72 million shs
Market Capitalization
$1.68 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.12
Consensus Rating
Hold

Company Overview

Sarepta Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
92nd Percentile Overall Score

SRPT MarketRank™: 

Sarepta Therapeutics scored higher than 92% of companies evaluated by MarketBeat, and ranked 161st out of 1,836 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sarepta Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.10, and is based on 8 buy ratings, 16 hold ratings, and 5 sell ratings.

  • Amount of Analyst Coverage

    Sarepta Therapeutics has been the subject of 29 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Sarepta Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Sarepta Therapeutics are expected to grow by 309.74% in the coming year, from $2.67 to $10.94 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sarepta Therapeutics is -6.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sarepta Therapeutics is -6.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sarepta Therapeutics has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Sarepta Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    15.12% of the outstanding shares of Sarepta Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Sarepta Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sarepta Therapeutics has recently increased by 1.23%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Sarepta Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Sarepta Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.12% of the outstanding shares of Sarepta Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Sarepta Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sarepta Therapeutics has recently increased by 1.23%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Sarepta Therapeutics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 87 news articles for Sarepta Therapeutics this week, compared to 22 articles on an average week.
  • Search Interest

    133 people have searched for SRPT on MarketBeat in the last 30 days. This is an increase of 108% compared to the previous 30 days.
  • MarketBeat Follows

    21 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sarepta Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.70% of the stock of Sarepta Therapeutics is held by insiders.

  • Percentage Held by Institutions

    86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Sarepta Therapeutics' insider trading history.
Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Stock News Headlines

Market Crash Warning: How to Protect Your Wealth Before August 12th
New China tariffs hit August 12th—and Wall Street’s already moving. Banks and billionaires are quietly shifting out of stocks, while everyday investors remain exposed. A free guide reveals where the smart money is going—and how to protect your wealth before the next sell-off.
See More Headlines

SRPT Stock Analysis - Frequently Asked Questions

Sarepta Therapeutics' stock was trading at $121.59 on January 1st, 2025. Since then, SRPT shares have decreased by 85.9% and is now trading at $17.10.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) issued its quarterly earnings data on Tuesday, May, 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of $2.20 by $5.62. Sarepta Therapeutics's revenue for the quarter was up 80.2% on a year-over-year basis.
Read the conference call transcript
.

The following companies are subsidiaries of Sarepta Therapeutics: Myonexus Therapeutics, Eisai, Sarepta Securities Corp., Sarepta Therapeutics Three LLC, and ST International Holdings Two Inc..

Top institutional investors of Sarepta Therapeutics include Aberdeen Group plc (1.26%), Y Intercept Hong Kong Ltd (0.89%), Assenagon Asset Management S.A. (0.88%) and Retirement Systems of Alabama (0.12%). Insiders that own company stock include Douglas S Ingram, Michael Andrew Chambers, Richard Barry, Ian Michael Estepan, Claude Nicaise, Hans Lennart Rudolf Wigzell, Bilal Arif, Dallan Murray, Ryan Edward Brown, Stephen Mayo and Kathryn Jean Boor.
View institutional ownership trends
.

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sarepta Therapeutics investors own include Zomedica (ZOM), NVIDIA (NVDA), Humana (HUM), American Water Works (AWK), Meta Platforms (META), Voyager Therapeutics (VYGR) and Waste Connections (WCN).

Company Calendar

Last Earnings
5/06/2025
Today
8/04/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SRPT
Previous Symbol
NASDAQ:AVII
CIK
873303
Employees
1,372
Year Founded
1980

Price Target and Rating

High Price Target
$160.00
Low Price Target
$13.00
Potential Upside/Downside
+187.3%
Consensus Rating
Hold
Rating Score (0-4)
2.10
Research Coverage
29 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.69)
Trailing P/E Ratio
N/A
Forward P/E Ratio
6.40
P/E Growth
N/A
Net Income
$235.24 million
Net Margins
-11.12%
Pretax Margin
-7.35%
Return on Equity
-14.88%
Return on Assets
-5.12%

Debt

Debt-to-Equity Ratio
1.00
Current Ratio
4.02
Quick Ratio
2.46

Sales & Book Value

Annual Sales
$1.90 billion
Price / Sales
0.88
Cash Flow
$2.62 per share
Price / Cash Flow
6.53
Book Value
$15.99 per share
Price / Book
1.07

Miscellaneous

Outstanding Shares
98,280,000
Free Float
90,710,000
Market Cap
$1.68 billion
Optionable
Optionable
Beta
0.46

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:SRPT) was last updated on 8/5/2025 by MarketBeat.com Staff
From Our Partners